DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Rebif (Interferon Beta-1a) - Current Clinical Trials

 
 



Rebif Related Clinical Trials

Rebif New Formulation (RNF) Quality of Life Study [Active, not recruiting]

Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis [Completed]

Transition to Rebif New Formulation [Active, not recruiting]

Avonex (Interferon-Beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-Remitting MS [Active, not recruiting]

Phase II Cladribine Add-on to Inteferon-Beta (IFN-b) Therapy in MS Subjects With Active Disease [Recruiting]

Post-authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif® [Recruiting]

Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS) [Recruiting]

Post Marketing Surveillance Study to Evaluate the Tolerability of Rebifďż˝ New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting. [Recruiting]

Pharmacokinetics and Pharmacodynamics of the Interferon Beta-1a Produced by Laboratorio Quimico Farmaceutico Bergamo Compared to Interferon Beta-1a (Rebif - Merck Serono) in Healthy Subjects [Recruiting]

Combination Therapy Using Cellcept and Rebif in RRMS [Recruiting]

Supplementation of VigantOLďż˝ Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebifďż˝ Treatment [Recruiting]

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis [Recruiting]

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis [Recruiting]

Tolerability of Rebif® (Interferon-beta 1-A) Therapy in Korean Patients With Multiple Sclerosis [Recruiting]

Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a? [Completed]

A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-Remitting Multiple Sclerosis (MS) [Completed]

Study of Rebif® Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone [Active, not recruiting]

Minocycline as add-on to Interferon Beta-1a (Rebif®) in Relapsing Remitting Multiple Sclerosis [Recruiting]

Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial [Recruiting]

Rebif Compliance Support Program - Assessing Needs in Multiple Sclerosis [Recruiting]

A Study of Avonex® to Determine the Effects of Dose Titration on the Incidence of Flu Like Symptoms in Healthy Volunteers [Recruiting]

Combination Treatment of Relapsing-Remitting Multiple Sclerosis With Methylprednisolone and Interferon-Beta-1a [Recruiting]

Effect of Interferon Beta-1a (Avonex®) on Changes of Non-Conventional MRI Measures in Patients With MS [Completed]

A Prospective Study Looking at the Use of Rebif® in Subjects With Clinically Isolated Syndrome [Active, not recruiting]

Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy [Completed]

A Study to Evaluate Rebif® New Formulation (IFN-Beta-1a) in Relapsing Remitting Multiple Sclerosis [Active, not recruiting]

An Observational Study for the Assessment of Adherence, Effectiveness and Convenience of Rebif® Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmart™. [Recruiting]

Minocycline as Add-on to Interferon-Beta-1a (Rebif®) in RRMS (Recycline) [Recruiting]

A Phase II Study Comparing Low- and High-Dose CAMPATH and High-Dose Rebif in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis [Active, not recruiting]

A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects [Recruiting]

Assessing Tolerability of Avonex Intramuscular Injections [Recruiting]

AVONEX® Combination Trial - "ACT" [Completed]

Safety and Efficacy of Treatment With Interferon Beta-1a Rebif® in Patients With Crohn’s Disease [Terminated]

A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly [Recruiting]

Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis [Active, not recruiting]

Safety Study in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif [Recruiting]

RNF and Betaseron® Tolerability Study [Active, not recruiting]

Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One [Recruiting]

A Phase 2 Study of Avonex in Ulcerative Colitis [Recruiting]

Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two [Recruiting]

RebiSmart Device Adherence Trial [Recruiting]

Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a [Recruiting]

Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM) [Completed]

Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis [Not yet recruiting]

Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) [Completed]

REbif FLEXible Dosing in Early Multiple Sclerosis (MS) [Recruiting]

How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose [Recruiting]

Rebif New Formulation in Relapsing Forms of Multiple Sclerosis [Completed]

A Multicenter, Randomized Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Tolerability, and Efficacy of AVONEX in Subjects With Moderate to Severe Ulcerative Colitis [Recruiting]

Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis [Completed]

Avonex PEN Satisfaction and Patients Experience Clinical Trial [Recruiting]

Safety Study of Interferon Beta 1a to for Acute Stroke [Active, not recruiting]

Pregnancy Exposure Registry for AVONEX [Recruiting]

Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event. [Not yet recruiting]

Simvastatin as an Add-on Treatment to Interferon-Beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis [Recruiting]

Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) Subjects [Terminated]

EARLY IFNb-1a and Atorvastatin Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis [Recruiting]

12-Week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis. [Recruiting]

Clinical 15 Months Study Comparing Monthly Pulse ACTH (Acthar Gel) Therapy With Monthly Methylprednisolone (MP, Solumedrol) for Multiple Sclerosis (MS) Patients Who Are on Regular Beta-interferons (Avonex, Betaseron or Rebif) [Recruiting]

Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS) [Not yet recruiting]

Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis [Active, not recruiting]

Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis [Recruiting]

Safety and Tolerability of Interferon-Beta-1a and Estroprogestins Association in MS Patients [Recruiting]

Rebif® Pregnancy Registry [Completed]

A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis [Recruiting]

An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These Parameters [Recruiting]

Safety and Efficacy of Interferon Beta-1a Rebif® for Treating Patients With Acute Symptoms of Ulcerative Colitis [Completed]

Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis [Recruiting]

EARLY IFNB-1a and Simvastatin Combination Therapy in Clinically Isolated Syndrome Suggestive of Multiple Sclerosis [Completed]

A Multicentre Phase III Study of Interferon-Beta-1a for the Treatment of Chronic Hepatitis C in Asian Patients [Completed]

The Neuroprotective Effect of Lamotrigine and Interferon Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis [Recruiting]

A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a [Not yet recruiting]

Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis [Completed]

A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis [Recruiting]

Determine Subject Satisfaction in Using the Single-Use Autoinjector With Pre-Filled Liquid Avonex in Subjects With Multiple Sclerosis [Recruiting]

BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®) [Recruiting]

Is IFN-Beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta [Active, not recruiting]

Neuroprotection With Riluzole Patients With Early Multiple Sclerosis [Recruiting]

Canadian Avonex PEN Productivity Study [Recruiting]

Safety/Effectiveness of Adding Monthly Dexamethasone to Weekly Avonex for MS [Recruiting]

Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx [Recruiting]

A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis [Recruiting]

Avonex 15 Year Long Term Follow-up Study [Recruiting]

An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF) [Recruiting]

Long-Term Follow-Up of Patients Who Participated in Study 27025 (REFLEX) [Recruiting]

Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept in Patients With Multiple Sclerosis [Completed]

An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis [Terminated]

An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-Remitting MS [Completed]

Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis [Recruiting]

Tolerability of Rebif® Injection With and Without the Use of Rebiject™ Mini in Relapsing Remitting Multiple Sclerosis Patients [Completed]

Combination Therapy (Provigil + Avonex) to Treat Cognitive Problems in MS [Recruiting]

COMPliance With Avonex® PS in Patients With Relapsing-Remitting MS [Recruiting]

EMEA Post Approval Commitment [Completed]

A Safety Study of Combination Treatment With Avonex and Zocor in Relapsing Remitting Multiple Sclerosis [Recruiting]

Omega-3 Fatty Acid Treatment in Multiple Sclerosis [Completed]

The Multicenter, Open-label, Single-use Autoinjector Convenience Study [Not yet recruiting]

fMRI Study of Treatment Recommendations Comparing Recently Diagnosed MS Patients to Controls [Recruiting]

Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study [Recruiting]

GER-009-06-AVX Early Therapy in Multiple Sclerosis [Active, not recruiting]

Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis [Recruiting]

Efficacy and Safety Study of BIIB017 [Recruiting]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012